Onconetix, Inc. Deferred Foreign Income Tax Expense (Benefit)
Onconetix, Inc. (ONCO) reported Deferred Foreign Income Tax Expense (Benefit) of $127.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-06-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2025-06-12
- Onconetix, Inc. deferred foreign income tax expense (benefit) for the quarter ending 2024-03-31 was $127.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 3 month |
|---|---|
| 2024-03-31 | $127.00K 10-Q · filed 2025-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |